Article content material
YONGIN, South Korea — GC Biopharma (006280.KS), a South Korean biopharmaceutical firm, takes half in a marketing campaign to have fun World Hemophilia Day.
Began in 1989 by the World Federation of Hemophilia (WFH) in honor of their founder Frank Schnabel’s birthday, World Hemophilia Day is widely known yearly on April 17 to lift consciousness of the illness and different bleeding problems.
The slogan of this yr is “Entry of all: Partnership. Coverage. Progress.” The slogan emphasizes its sustainable administration and therapeutic system by way of a nationwide degree coverage for bleeding problems, together with hemophilia.
Article content material
Within the sense of supporting hemophilia group, the corporate posts this yr’s slogan picture on large exterior media façade of its major campus in Yongin, South Korea.
“We’re proud to take part within the marketing campaign to foster solidarity and hope among the many hemophilia group,” stated Eun Chul Huh, Ph. D., President GC Biopharma. “We might be chargeable for enhancing the standard of hemophilia sufferers’ lives.”
About Hemophilia
Hemophilia is a congenital dysfunction that causes longer-than-normal bleeding attributable to absent or poor clotting issue within the blood. Hemophilia A is extra widespread than hemophilia B; hemophilia A impacts about 150,000 folks, whereas hemophilia B impacts about 30,000 folks worldwide. Remedy regimens sometimes embrace on-demand and/or common prophylactic infusions of issue alternative remedy to manage or forestall the danger of bleeding. Folks with hemophilia, working intently with their healthcare professionals, can stay wholesome lives with correct care and satisfactory therapy.
About GC Biopharma
GC Biopharma (previously referred to as Inexperienced Cross Company) is a biopharmaceutical firm that delivers life-saving and life-sustaining protein therapeutics and vaccines. Headquartered in Yongin, South Korea, GC Biopharma is likely one of the main plasma protein and vaccine product producers globally and has been devoted to high quality healthcare options for greater than half a century.
This press launch might comprise forward-looking statements, which categorical the present beliefs and expectations of GC Biopharma’s administration. Such statements don’t symbolize any assure by GC Biopharma or its administration of future efficiency and contain recognized and unknown dangers, uncertainties and different components. GC Biopharma undertakes no obligation to replace or revise any forward-looking assertion contained on this press launch or another forward-looking statements it might make, besides as required by regulation or inventory alternate rule.
View supply model on businesswire.com: https://www.businesswire.com/information/house/20220416005013/en/
Contacts
Investor/Media Contact
Yelin Jun
yelin@gccorp.com
Sohee Kim
shkim20@gccorp.com
Hansaem Kim
hs.kim@gccorp.com
Haeun Yoon
cutty980117@gccorp.com
Minhyoung Kim
minhkim@gccorp.com
#distro
